Evofem Q2 FY26 net loss widens to $8.55 million; net product sales fall 45% to $2.63 million

• Evofem posted Q2 net product sales of $2.63 million, down 45% year over year.
• Cost of goods sold fell 32% to $511,000, partly offset by a $100,000 write-off of excess SOLOSEC inventory.
• Total other expense widened to $8.55 million from $526,000, driven by a $5.7 million fair-value loss on financial instruments.
• First-half net product sales dropped 38% to $3.53 million; total other expense swung to a $9.44 million loss from $103,000 income.
• June 30 restricted cash and cash equivalents were $300,000, with management citing insufficient liquidity for the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038328), on August 14, 2026, and is solely responsible for the information contained therein.